Browsing by Author Atkinson, Victoria

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2017Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanomaKefford, Richard (Rick); Long, Georgina; Atkinson, Victoria; Chiarion-Sileni, Vanna; Dutriaux, Caroline; et al, Various; Hauschild, Axel; Haydon, Andrew; Larkin, J; MandalĂ , Mario; Nyakas, Marta; Santinami, Mario; Western Clinical School: Medicine (Westmead); Northern Clinical School: MedicineAdjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma, New England Journal of Medicine, vol.377, 19, 2017,pp 1813-1823
2016Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapyCarlino, Matteo; Long, Georgina; Atkinson, Victoria; Bowyer, Samantha; et al, .; Khou, M.; Larkin, James; Lorigan, Paul; McArthur, Grant A.; Millward, Michael; Prithviraj, P.; Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer CentreEfficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy, British Journal of Cancer, vol.114, 10, 2016,pp 1084-1089
2017Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trialCarlino, Matteo; Guminski, Alexander; Kong, Benjamin; Lomax, Anna; Long, Georgina; McNeil, Catriona; Menzies, Alexander Maxwel; Atkins, Michael B; Atkinson, Victoria; Cebon, Jonathan Simon; Ebbinghaus, Scot; Fitzharris, Bernie; Hill, A; Hodi, F. Stephen; Hwu, Wen-Jen; Ibrahim, Nageatte; Islam, Mohammed; Jameson, Michael B; Kefford, Richard; Ribas, Antoni; Shu, Xinxin; Srivastava, Archana; Tamjid, Babak; Thompson, John; Westmead Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Office; Central Clinical School: Melonoma & Skin Cancer Res. Inst.; Northern Clinical School: Medicine; Central Clinical School: Medicine; Northern Clinical School: MedicineStandard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial, The Lancet Oncology, vol.18, 9, 2017,pp 1202-1210